← Back to Search

11C-PBR28 for Alzheimer's Disease

Phase 2

Waitlist Available

Led By William C Kreisl, MD

Research Sponsored by William Charles Kreisl

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year from screening

Awards & highlights

Study Summary

This trial is studying inflammation and amyloid in Alzheimer's disease by measuring it with a PET scan.

Eligible Conditions

Alzheimer's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year from screening

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year from screening

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year from screening for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

11C-PBR28 binding (standardized uptake value ratio)

Secondary outcome measures

18F-Florbetaben binding (standardized uptake value ratio)

Cerebral spinal fluid (CSF) biomarkers

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Cognitive impairmentExperimental Treatment3 Interventions

Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology

Group II: No cognitive impairmentActive Control3 Interventions

Normal aging

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

11C-PBR28

2015

Completed Phase 2

~10

Florbetaben (18F)

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

William Charles KreislLead Sponsor

6 Previous Clinical Trials

456 Total Patients Enrolled

James M Noble, MD, MS, CPH, FAANLead Sponsor

2 Previous Clinical Trials

175 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,665 Previous Clinical Trials

28,004,979 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being considered for enrollment in this research project?

"This particular trial is no longer searching for participants. Originally posted on June 1st 2016 and last updated in September 2022, the study has concluded its recruitment process. If you are looking to explore other studies with similar conditions, there are 895 trials actively recruiting those suffering from Alzheimer's disease as well as 7 clinical trials administering 18F-Florbetaben presently accepting new patients."

Answered by AI

Has the FDA granted authorization for 18F-Florbetaben?

"With a score of 2, the safety profile of 18F-Florbetaben is estimated to be mid-level. This assessment reflects the fact that Phase 2 clinical data supports its security but not necessarily its efficacy."

Answered by AI

Is there still capacity within this research to admit participants?

"At the current moment, this clinical trial is not actively recruiting patients. The original post date was June 1st 2016 while the most recent update occured on September 16th 2022. If searching for alternative studies, there are 895 trials with open enrollment related to Alzheimer's and 7 trials involving 18F-Florbetaben that are still welcoming participants."

Answered by AI

Is this particular medical trial unique in its scope?

"Presently, 7 trials are being conducted with 18F-Florbetaben in 3 cities over 2 nations. Bayer were the sponsors of the initial research back in 2010, a study that involved 161 subjects and ended at its drug approval phase. Subsequently, 13 experiments have been wrapped up since then."

Answered by AI

Are there any past research efforts involving 18F-Florbetaben?

"Presently, there exist 7 clinical trials in progress for 18F-Florbetaben with none of them having reached the third stage. With 9 trial sites across Philadelphia, Pennsylvania, this medication is undergoing rigorous testing."

Answered by AI

Recent research and studies

Journal of Alzheimer's DiseaseJournal

Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer’s Disease

Klein, Julia, Xinyu Yan, Aubrey Johnson, Zeljko Tomljanovic, James Zou, Krista Polly, Lawrence S. Honig, et al.. 2021. “Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer’s Disease”. Edited by Brian Gordon. Journal of Alzheimer's Disease. IOS Press. doi:10.3233/jad-201149.

clinicaltrials.govStudy

Imaging Inflammation in Alzheimer's Disease

James M Noble, MD, MS, CPH, FAAN 2016. "Imaging Inflammation in Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02831283.